Resonant Link Medical

Resonant Link operates at the intersection of medical-device power, industrial charging, electric-vehicle infrastructure, and wireless electronics. Its clearest differentiation is technical breadth: the company applies one wireless-power architecture across millimeter-scale implants, implantable pulse generators, artificial-heart systems, lift trucks, autonomous vehicles, drones, and other high-demand applications. The stated performance claims include up to 5x faster or higher-performing wireless power and a multilayer self-resonant structure that can achieve up to 6x higher Q than conventional charging coils. The medical portfolio is particularly differentiated by MRI-compatible charging, contactless power delivery, and the potential to eliminate drivelines in ventricular assist devices and total artificial hearts. Relative to conventional wired charging and standard wireless-coil designs, Resonant Link emphasizes higher power density, improved alignment tolerance, multi-MHz power electronics, and operation in mission-critical settings. Its competitive challenge is execution: medical applications require validation, regulatory progress, device-maker integration, and long commercialization cycles, while industrial and EV markets demand manufacturing scale and interoperability.

Resonant Link’s trajectory shows a transition from university-derived wireless-power research into a multi-market commercialization platform. Founded in 2017, the company secured a $224,997 grant in 2018 and a pre-seed round in 2020 before raising $9.3 million in Seed funding on Feb 2, 2022. A convertible note followed on Sep 15, 2022, and a $3.425 million Series A closed on Jan 28, 2025, bringing total recorded funding to $12,949,997 across six rounds, including grants. The January 2025 financing is an important inflection point because it coincided with a more explicit emphasis on medical applications. That focus became organizationally visible in 2025: Omari Bouknight was appointed CEO on Apr 8, 2025, and Resonant Link Medical was launched on Nov 5, 2025 with Raymond Cohen as board chair. Product breadth remains a growth asset, covering implant chargers as well as systems for lift trucks, automated vehicles, drones, and high-power transportation. However, the available employee range remains 11–50 and hiring information is limited, so evidence of operating-scale expansion is weaker than the funding and leadership signals. Patent activity in 2024 and 2025 supports continued technical development.